The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction

Diabetes Care

Volumn 41, Issue 1, 2018, Pages 150-155

  Sandesara, Pratik B ^a   O'Neal, Wesley T ^a   Kelli, Heval M ^a   Samman Tahhan, Ayman ^a   Hammadah, Muhammad ^a   Quyyumi, Arshed A ^a   Sperling, Laurence S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SPIRONOLACTONE; CREATININE; INSULIN; MINERALOCORTICOID ANTAGONIST;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; HAZARD RATIO; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROANGIOPATHY; OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SELF REPORT; BIOASSAY; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETIC COMPLICATION; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; CREATININE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INSULIN; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROGNOSIS; RISK FACTORS; STROKE VOLUME;

EID: 85038937860     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0755     Document Type: Article

References (16)

1. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014; 64: 2281-2293
2. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014; 115: 79-96
3. Samson R, Jaiswal A, Ennezat PV, Cassidy M, Le Jemtel TH. Clinical phenotypes in heart failure with preserved ejection fraction. J AmHeart Assoc 2016; 5: e002477
4. Brownrigg JR, Hughes CO, Burleigh D, et al. Microvascular disease, and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 2016; 4: 588-597
5. Kristensen SL, Mogensen UM, Jhund PS, et al. Clinical, and echocardiographic characteristics, and cardiovascular outcomes according to diabetes status in patientswith heart failure, and preserved ejection fraction: a report from the Irbesartan in Heart Failure with Preserved Ejection Fraction Trial (I-Preserve). Circulation 2017; 135: 724-735
6. Desai AS, Lewis EF, Li R, et al. Rationale, and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patientswith symptomatic heart failure, and preserved ejection fraction. Am. Heart J 2011; 162: 966-972. e910
7. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013; 6: 184-192
8. Pitt B, Pfeffer MA, Assmann SF, et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-1392
9. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients, and outcomes in the Treatment of Preserved Cardiac Function Heart FailureWith an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42
10. MacDonald MR, Petrie MC, Varyani F, et al. CHARM Investigators. Impact of diabetes on outcomes in patients with low, and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality, and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385
11. Brownlee M. Biochemistry andmolecular cell biology of diabetic complications. Nature 2001; 414: 813-820
12. MacDonald MR, Petrie MC, Home PD, et al. Incidence, and prevalence of unrecognizedmyocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes, and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care 2011; 34: 1394-1396
13. Davis TM, Coleman RL, Holman RR; UKPDS Group. Prognostic significance of silentmyocardial infarction in newly diagnosed type 2 diabetesmellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation 2013; 127: 980-987
14. Scirica BM, Bhatt DL, Braunwald E, et al. SAVOR-TIMI 53 Steering Committee, and Investigators. Saxagliptin, and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326
15. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J 2010; 31: 824-831
16. Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-e239